Globeflex Capital’s Standard BioTools LAB Stock Holding History

Globeflex Capital’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-37	Closed	-$1K	–	647
2014 Q1	$1K	Buy	+37	New	+$1.63K	﹤0.01%	523

Other funds holding LAB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

NCGI

Next Century Growth Investors Plymouth, Minnesota $1.38B AUM 102.34% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Globeflex Capital's LAB Position: Q2 2014 in Review

Globeflex Capital sold out of Standard BioTools (LAB) in Q2 2014, closing a stake of 37 shares — an estimated $1K sold.

Globeflex Capital first reported a position in LAB in Q1 2014 and held it in 1 quarter. The position peaked at $1K in Q1 2014. 104 funds tracked by Wall St. Rank hold LAB as of Q2 2014.

Globeflex Capital reported no remaining Standard BioTools position as of Q2 2014 after selling out during the quarter.
Globeflex Capital sold 37 Standard BioTools shares in Q2 2014, an estimated $1K.
Globeflex Capital first reported a position in Standard BioTools in Q1 2014 and held it in 1 quarter.
Globeflex Capital's Standard BioTools position peaked at $1K in Q1 2014.
104 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2014.

Based on Globeflex Capital's 13F filing for Q2 2014, filed 18 Jul 2014.